EANS-News: Epigenomics AG: Noel Doheny Appointed as New CEO of US-Subsidiary Epigenomics Inc.

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Personnel/Molecular diagnostics

Berlin, Germany, and Seattle, WA, USA, April 20, 2011 (euro adhoc) -
Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer diagnosis
company, today announced the appointment of Noel Doheny as the new
Chief Executive Officer (CEO) of its subsidiary Epigenomics Inc. in
Seattle, WA, USA, reporting to Geert Nygaard, CEO of Epigenomics AG.
Mr. Doheny will start in his new position in early May 2011.

Mr. Doheny has 30+ years of experience in the field of diagnostics,
with over 20 years in senior management. In his most recent position
as CEO of OpGen (2008-2009), Mr. Doheny led the transformation of an
incubator lab services company into a systems company in less than
two years. Prior to this, he held positions as Senior Vice President
for the Molecular Diagnostics Division of Affymetrix Inc., Vice
President of Pre-Analytical Solutions and a member of the Executive
Committee at QIAGEN as well as President and CEO of BioStar Inc.
(known as ThermoBioStar post-acquisition). Importantly for
Epigenomics as it continues to build a US sales force, he has built
several operating teams from the ground up, including the commercial
teams to launch novel products at companies such as Ciba Corning,
ThermoBiostar, and OpGen. Mr. Doheny obtained degrees in Biology and
Chemistry from West Virginia University and attended Georgetown
University for post-graduate studies in Biochemistry prior to moving
into industry.

"With the Company gearing up for the pre-market approval submission
of Epi proColon® 2.0 to the FDA, I am absolutely delighted to be
given this opportunity to build the commercial strategy and the team
for a successful launch of the test in the USA and very much look
forward to joining Epigenomics´ management team," commented Noel
Doheny on his appointment as CEO of Epigenomics Inc.

Geert Nygaard, Chief Executive Officer of Epigenomics said: "I would
like to welcome Noel as the new CEO of our U.S.-based subsidiary,
Epigenomics Inc., who comes with a very strong commercial background
with broad scientific and medical expertise. Noel´s extensive
experience in the diagnostics industry, along with his marketing and
sales know-how, will be instrumental in helping us strengthen our
commercial operations in the US and driving the transformation of
that organization into a commercial molecular diagnostics enterprise.
We are pleased to welcome him to the team and believe that his
experience will be crucial at this pivotal stage of the company."

-Ends-

Contact Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368
pr@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing

and commercializing a pipeline of proprietary products for cancer.
The Company´s products enable doctors to diagnose cancer earlier and
more accurately, leading to improved outcomes for patients.
Epigenomics´ lead product, Epi proColon®, is a blood-based test for
the early detection of colorectal cancer, which is currently marketed
in Europe and is in development for the U.S.A. The Company´s
technology and products have been validated through multiple
partnerships with leading global diagnostic companies including
Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an
international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimer. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward- looking statements contained herein as a result of new
information, future events or otherwise.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade